Efficacy and Tolerance of Intradermal Versus Intramuscular Hepatitis B Immunization: A Randomized Study

  • R. Darioli
  • P. Bovet
  • P.-A. Raeber
  • D. Lavanchy
  • Ph. Frei


The intradermal route has been successfully used for immunization against several infectious diseases [1–3]. Preliminary trials with small numbers of healthy individuals show that reduced doses of hepatitis B vaccine administered intradermally (i.d.) produce a similar seroconversion rate (83%–100%) to that given by intramuscular (i.m.) injection of 20 µg HBs Ag in seronegative subjects [4–7]. Nevertheless, low doses of i.d. vaccine seem to result in lower anti-HBs levels [5, 8] and several objections are raised concerning the use of the i.d. route for HBV vaccination [9, 10]. The aim of this study was to compare the efficacy and tolerance of the standard dose of 20 µg H-B-VAX inoculated either i.d. or i.m. in healthy subjects.


Seroconversion Rate High Immune Response Seronegative Subject Frequent Adverse Reaction Intradermal Route 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nicholson KG, Prestage H, Cole PJ, Turner GS, Bauer SP (1981) Multisite intradermal antirabies vaccination. Lancet 11:915–917CrossRefGoogle Scholar
  2. 2.
    Iwarson S, Larsson P (1980) Intradermal versus subcutaneous immunization with typhoid vaccine. J Hyg 84:11–16CrossRefGoogle Scholar
  3. 3.
    Clasener HAL, Bennders BJW (1967) Immunization of man with typhoid and cholera vaccine. Agglutination antibodies after intracutaneous and subcutaneous injection. J Hyg 65:449CrossRefGoogle Scholar
  4. 4.
    Miller KD, Gibbs RD, Mulligan MM, Nutmann TB, Francis DP (1983) Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet 11:1454–1456CrossRefGoogle Scholar
  5. 5.
    Redfield RR, Innis BL, Scott ERM, Cannon HG, Bancroft WH (1985) Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254:3203–3206PubMedCrossRefGoogle Scholar
  6. 6.
    Zoulek G, Lorbeer B, Jilg W, Deinhardt F (1984) Evaluation of reduced dose of hepatitis B vaccine administered intradermally. J Med Virol 14:27–32PubMedCrossRefGoogle Scholar
  7. 7.
    Irving WL, Alder M, Kurtz JB, Juel-Jensen B (1986) Intradermal vaccination against hepatitis B. Lancet 11:1340CrossRefGoogle Scholar
  8. 8.
    Zoulek G, Lorbeer B, Jilg W, Deinhardt F (1984) Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine. Lancet 11:983–984CrossRefGoogle Scholar
  9. 9.
    Dienstag JL (1986) Low-dose intradermal hepatitis B vaccine. JAMA 256:351PubMedCrossRefGoogle Scholar
  10. Zuckermann AJ (1987) Appraisal of intradermal immunization against hepatitis B. Lancet 1:435CrossRefGoogle Scholar
  11. 10.
    Update on hepatitis B prevention (1987). MMWR 36:353–360Google Scholar
  12. 11.
    Gaudeau A, Dubois F, Louq MC, Mozert MC (1984) Immunogenicity of a low-dose (1.25 and 0.31 ug) hepatitis B vaccine. Lancet 11:1091–1092CrossRefGoogle Scholar
  13. 12.
    Halsey NA, Reppert EJ, Margolis HS, Francis DP, Fields HA (1986) Intradermal hepatitis B vaccination in abbreviated schedule. Vaccine 4:228–232PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • R. Darioli
  • P. Bovet
  • P.-A. Raeber
  • D. Lavanchy
  • Ph. Frei

There are no affiliations available

Personalised recommendations